Aurinia Pharmaceuticals Inc $AUPH Stake Trimmed by Geode Capital Management LLC
Geode Capital Management LLC reduced its stake in Aurinia Pharmaceuticals Inc by 9.1% during Q2, owning 1,577,060 shares worth $13.35 million. Other hedge funds have also adjusted their positions in AUPH. Analysts have mixed ratings on the stock, with a consensus 'Hold' rating and a target price of $17.67. Aurinia's Q3 earnings beat estimates, reporting $0.23 EPS and $73.47 million revenue.
Geode Capital Management LLC lessened its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 9.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,577,060 shares of the biotechnology company's stock after selling 157,240 shares during the period. Geode Capital Management LLC owned about 1.20% of Aurinia Pharmaceuticals worth $13,355,000 at the end of the most recent reporting period.
- These 2 Healthcare Stocks Have Doubled in 2023
A number of other hedge funds also recently bought and sold shares of AUPH. MAI Capital Management acquired a new position in shares of Aurinia Pharmaceuticals in the first quarter worth about $39,000. Mackenzie Financial Corp acquired a new position in Aurinia Pharmaceuticals in the 1st quarter worth approximately $86,000. Vanguard Personalized Indexing Management LLC purchased a new position in Aurinia Pharmaceuticals during the 2nd quarter worth approximately $92,000. Teza Capital Management LLC acquired a new stake in Aurinia Pharmaceuticals during the 1st quarter valued at $96,000. Finally, Martingale Asset Management L P acquired a new stake in Aurinia Pharmaceuticals during the 1st quarter valued at $99,000. 36.83% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on AUPH shares. Bloom Burton downgraded Aurinia Pharmaceuticals from a "moderate buy" rating to a "hold" rating in a report on Wednesday, November 5th. Jefferies Financial Group upgraded Aurinia Pharmaceuticals from a "hold" rating to a "buy" rating and raised their price objective for the stock from $10.00 to $21.00 in a research report on Friday, November 7th. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $15.00 target price (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 5th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $17.67.
Get Our Latest Report on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Stock Performance
Shares of NASDAQ AUPH opened at $16.17 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. Aurinia Pharmaceuticals Inc has a one year low of $6.55 and a one year high of $16.48. The business's 50-day moving average price is $13.31 and its two-hundred day moving average price is $11.05. The company has a market capitalization of $2.13 billion, a P/E ratio of 37.61 and a beta of 1.30.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.07. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The business had revenue of $73.47 million during the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.
Aurinia Pharmaceuticals Company Profile
(Free Report)Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Recommended Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Congress Beat the Market Again—Here Are the 3 Stocks They Bought
- Growth Stocks: What They Are, Examples and How to Invest
- Go on a Shopping Spree With 3 Top Retail ETFs
Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Aurinia Pharmaceuticals Right Now?
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
